Prelude Therapeutics amends bylaws for universal proxy rules and DGCL updates

Prelude Therapeutics Inc

Amended bylaws effective Jan 19, 2023, addressing SEC universal proxy rules (Rule 14a-19) and recent DGCL amendments.
Revised advance notice provisions require additional disclosures, limit nominees to board seats available, and mandate nominee interviews.
New rule requiring universal proxy solicitors to use non-white proxy cards; stockholders must certify compliance with Rule 14a-19.
Added emergency bylaw provision for board/quorum during crises; updated electronic notice procedures.
Updates to stockholder meeting conduct, including attendance procedures and Rule 14a-8 proponent rules.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Prelude Therapeutics Inc: Adopted amended and restated bylaws to implement changes related to universal proxy rules, recent DGCL amendments, and other procedural and administrative updates, effective January 19, 2023 (effective 2023-01-19).

Change: bylaw amendment
Effective: 2023-01-19

Exact text from the filing

On January 19, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Prelude Therapeutics Incorporated (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-001023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.